News for Healthier Living

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Coho

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced positive topline results from the registrational ChonDRAgon study (n= 206) investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma.

October 23, 2025


November 5 2025

November 4 2025

November 3 2025

November 2 2025

November 1 2025

October 31 2025

October 30 2025

October 29 2025

October 28 2025

October 27 2025

October 26 2025

October 25 2025

October 24 2025

October 23 2025